Trials / Completed
CompletedNCT04499209
Pharmacokinetics Study of XG005 Capsule
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Xgene Pharmaceutical Group · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This was a Phase 1, single-center, randomized, placebo-controlled, 2-period, ascending single-dose study assessing the PK, safety, and tolerability of single ascending doses of XG005 (Period 1) and the naproxen and pregabalin combination (Period 2), in 5 dose groups each with 10 subjects.
Detailed description
Period 1 was double-blind and randomized 8 subjects (1:1 allocation ratio by gender) to XG005 and 2 subjects (1:1 allocation ratio by gender) to placebo. Subjects were enrolled sequentially into a total of 5 ascending dose levels pending safety review, and PK review where possible, of Period 1 of the prior dose level. Sentinel dose participants (1 for XG005 and 1 for placebo) were included as the first dose administered at each dose level in Period 1. In Period 2, all subjects in the last three XG005 dose groups received approximate molar equivalents of naproxen and pregabalin corresponding to XG005 doses after a 7-day washout period. Period 2 was open-label with 10 subjects per group. PK blood samples in each treatment period were collected at 0 (pre-dosing), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs after drug administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XG005 | XG005 Capsule |
| DRUG | Combination of Naproxen and Pregabalin | Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica |
| DRUG | Placebos | Placebo Capsule |
Timeline
- Start date
- 2017-10-16
- Primary completion
- 2018-01-18
- Completion
- 2018-03-19
- First posted
- 2020-08-05
- Last updated
- 2020-08-18
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04499209. Inclusion in this directory is not an endorsement.